Global ophthalmic drug delivery system market will reach $ 30,013.7 million by 2031, growing by 6.9% annually over 2021-2031, driven by the growing prevalence of ophthalmic diseases, the emerging novel ocular drug delivery systems, rise in number of ophthalmic procedures that require attentive post procedural care, and the increasing demand to deliver controlled dosage forms for pediatric and geriatric population.
Highlighted with 80 tables and 89 figures, this 196-page report 鈥淕lobal Ophthalmic Drug Delivery System 麻豆原创 2021-2031 by Product (Syringes, Eyedroppers, Dispensers, Sprayers, Contact Lenses, Inserts, Implants, Plugs), Dosage Form (Solutions, Gels, Ointments, Suspensions, Emulsions, Liposomes & Nanoparticles), Disease (Glaucoma, Diabetic Retinopathy, Cataract, Dry Eye Syndrome, Macular Degeneration, Diabetic Macular Edema, Refractive Issues), Setting (Hospitals, Clinics, 麻豆原创care Settings, ASCs, Others), and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global ophthalmic drug delivery system market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global ophthalmic drug delivery system market in every aspect of the classification from perspectives of Product, Dosage Form, Disease, Setting, and Region.
Based on Product, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Pre-filled Syringes
鈥� Multidose Eyedroppers
鈥� Squeeze Dispensers
鈥� Mist Sprayers
鈥� Contact Lenses
鈥� Ocular Inserts
鈥� Intraocular Implants
鈥� Punctal Plugs
鈥� Other Products
Based on Dosage Form, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Solutions
鈥� Gels
鈥� Ointments
鈥� Suspensions
鈥� Emulsions
鈥� Liposomes & Nanoparticles
By Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Glaucoma
鈥� Diabetic Retinopathy
鈥� Cataract
鈥� Dry Eye Syndrome
鈥� Macular Degeneration
鈥� Diabetic Macular Edema
鈥� Refractive Issues
鈥� Other Diseases
By Setting, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Hospitals
鈥� Clinics
鈥� 麻豆原创care Settings
鈥� Ambulatory Surgical Centers (ASCs)
鈥� Other Settings
Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (Israel, UAE锛孲audi Arabia, South Africa and Rest of MEA)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of each national market by Product, Dosage Form and Setting over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Aero Pump GmbH
Allergan plc.
AptarGroup, Inc.
Becton, Dickinson and Company
Biocorp
Clearside Biomedical, Inc.
EyePoint Pharmaceuticals, Inc.
Gaplast GmbH
Gerresheimer AG
Jotteq Inc.
Kedalion Therapeutics, Inc.
Mati Therapeutics, Inc.
Nemera
Nipro Corporation
Ocular Therapeutix, Inc.
Ocumedic, Inc.
Owen Mumford
Re-Vana Therapeutics
Silgan Holdings Inc.
Terumo Corporation
Valeant Pharmaceuticals International Inc. (Bausch Health Company)
West Pharmaceutical Services, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of 麻豆原创 Research Methodology 13
1.2.2 麻豆原创 Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 麻豆原创 Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 麻豆原创 Overview and Dynamics 21
2.1 麻豆原创 Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the 麻豆原创 25
2.2 Major Growth Drivers 27
2.3 麻豆原创 Restraints and Challenges 31
2.4 Emerging Opportunities and 麻豆原创 Trends 34
2.5 Porter鈥檚 Fiver Forces Analysis 38
3 Segmentation of Global 麻豆原创 by Product 42
3.1 麻豆原创 Overview by Product 42
3.2 Pre-filled Syringes 44
3.3 Multidose Eyedroppers 45
3.4 Squeeze Dispensers 46
3.5 Mist Sprayers 47
3.6 Contact Lenses 48
3.7 Ocular Inserts 49
3.8 Intraocular Implants 50
3.9 Punctal Plugs 51
3.10 Other Products 52
4 Segmentation of Global 麻豆原创 by Dosage Form 53
4.1 麻豆原创 Overview by Dosage Form 53
4.2 Solutions 55
4.3 Gels 56
4.4 Ointments 57
4.5 Suspensions 58
4.6 Emulsions 59
4.7 Liposomes & Nanoparticles 60
5 Segmentation of Global 麻豆原创 by Disease 61
5.1 麻豆原创 Overview by Disease 61
5.2 Glaucoma 63
5.3 Diabetic Retinopathy 64
5.4 Cataract 65
5.5 Dry Eye Syndrome 66
5.6 Macular Degeneration 67
5.7 Diabetic Macular Edema 68
5.8 Refractive Issues 69
5.9 Other Diseases 70
6 Segmentation of Global 麻豆原创 by Setting 71
6.1 麻豆原创 Overview by Setting 71
6.2 Hospitals 73
6.3 Clinics 74
6.4 麻豆原创care Settings 75
6.5 Ambulatory Surgical Centers (ASCs) 76
6.6 Other Settings 77
7 Segmentation of Global 麻豆原创 by Region 78
7.1 Geographic 麻豆原创 Overview 2021-2031 78
7.2 North America 麻豆原创 2021-2031 by Country 82
7.2.1 Overview of North America 麻豆原创 82
7.2.2 U.S. 86
7.2.3 Canada 90
7.2.4 Mexico 93
7.3 European 麻豆原创 2021-2031 by Country 96
7.3.1 Overview of European 麻豆原创 96
7.3.2 Germany 100
7.3.3 U.K. 103
7.3.4 France 106
7.3.5 Spain 109
7.3.6 Italy 112
7.3.7 Netherlands 115
7.3.8 Rest of European 麻豆原创 118
7.4 Asia-Pacific 麻豆原创 2021-2031 by Country 120
7.4.1 Overview of Asia-Pacific 麻豆原创 120
7.4.2 Japan 124
7.4.3 China 128
7.4.4 Australia 131
7.4.5 India 134
7.4.6 South Korea 137
7.4.7 Rest of APAC Region 140
7.5 South America 麻豆原创 2021-2031 by Country 142
7.5.1 Argentina 145
7.5.2 Brazil 148
7.5.3 Chile 151
7.5.4 Rest of South America 麻豆原创 154
7.6 MEA 麻豆原创 2021-2031 by Country 155
7.6.1 Israel 158
7.6.2 Saudi Arabia 161
7.6.3 South Africa 164
7.6.4 Other National 麻豆原创s 167
8 Competitive Landscape 168
8.1 Overview of Key Vendors 168
8.2 New Product Launch, Partnership, Investment, and M&A 172
8.3 Company Profiles 173
Aero Pump GmbH 173
Allergan plc. 175
AptarGroup, Inc. 176
Becton, Dickinson and Company 177
Biocorp 178
Clearside Biomedical, Inc. 179
EyePoint Pharmaceuticals, Inc. 180
Gaplast GmbH 181
Gerresheimer AG 182
Jotteq Inc. 183
Kedalion Therapeutics, Inc. 184
Mati Therapeutics, Inc. 185
Nemera 186
Nipro Corporation 187
Ocular Therapeutix, Inc. 188
Ocumedic, Inc. 189
Owen Mumford 190
Re-Vana Therapeutics 191
Silgan Holdings Inc. 192
Terumo Corporation 193
Valeant Pharmaceuticals International Inc. (Bausch Health Company) 194
West Pharmaceutical Services, Inc. 195
RELATED REPORTS 196
Selected Key Players:
Aero Pump GmbH
Allergan plc.
AptarGroup, Inc.
Becton, Dickinson and Company
Biocorp
Clearside Biomedical, Inc.
EyePoint Pharmaceuticals, Inc.
Gaplast GmbH
Gerresheimer AG
Jotteq Inc.
Kedalion Therapeutics, Inc.
Mati Therapeutics, Inc.
Nemera
Nipro Corporation
Ocular Therapeutix, Inc.
Ocumedic, Inc.
Owen Mumford
Re-Vana Therapeutics
Silgan Holdings Inc.
Terumo Corporation
Valeant Pharmaceuticals International Inc. (Bausch Health Company)
West Pharmaceutical Services, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
